1-3 of 3
Peter Kaatsch
Close
Sort by
Journal Articles

Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols

Brief Report
Martin Stanulla, Elke Schaeffeler, Anja Möricke, Sally A. Coulthard, Gunnar Cario, André Schrauder, Peter Kaatsch, Michael Dördelmann, Karl Welte, Martin Zimmermann, Alfred Reiter, Michel Eichelbaum, Hansjörg Riehm, Martin Schrappe, Matthias Schwab
Journal: Blood
Blood (2009) 114 (7): 1314–1318.
https://doi.org/10.1182/blood-2008-12-193250
Published: 2009
Journal Articles

Secondary Neoplasms Subsequent to Berlin-Frankfurt-Muenster (BFM) Therapy of Non-Hodgkin Lymphoma of Childhood: Significantly Higher Risk for Patients with Lymphoblastic Lymphoma Compared to Other NHL-Subtypes.

Olga Wachowski, MD, Martin Zimmermann, PhD, Birgit Burkhardt, MD, Olaf Determann, MD, Ulrike Meyer, Peter Kaatsch, PhD, Georg Mann, MD, Reza Parwaresch, MD, Hansjoerg Riehm, MD, Martin Schrappe, MD, Alfred Reiter, MD
Journal: Blood
Blood (2005) 106 (11): 232.
https://doi.org/10.1182/blood.V106.11.232.232
Published: 2005
Journal Articles

Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy

Clinical Trials & Observations
Lutz Löning, Martin Zimmermann, Alfred Reiter, Peter Kaatsch, Günter Henze, Hansjörg Riehm, Martin Schrappe
Journal: Blood
Blood (2000) 95 (9): 2770–2775.
https://doi.org/10.1182/blood.V95.9.2770.009k16_2770_2775
Published: 2000